Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company's oncology pipeline and focused approach to the research and development of po
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
08:23am, Monday, 03'rd Jun 2024
Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patient
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or d
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
04:29pm, Thursday, 30'th May 2024
Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stag
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
02:45pm, Thursday, 30'th May 2024
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
01:26pm, Thursday, 30'th May 2024
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
Merck Signs MoU with KAIST to Advance Scientific Collaboration
08:01pm, Wednesday, 29'th May 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Techno
Merck acquires EyeBio in up to $3B deal
04:06pm, Wednesday, 29'th May 2024
Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held ophthalmology-focused biotech firm, in a deal valued up to $3 billion. Through a subsidiary, Merck will acquire Ey
Merck Stock: Still Discounted To Graham P/E
01:43pm, Wednesday, 29'th May 2024
Merck stock is still a buy despite near-record stock prices. Thanks to its growth outlook, its current valuation is still far below the Graham P/E, leaving a wide margin of safety. Its well-balanced b
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
11:55am, Wednesday, 29'th May 2024
Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.
Merck to Buy Eye Drug Startup For Up to $3 Billion. It's Doubling Down on Deals.
08:44am, Wednesday, 29'th May 2024
The pharmaceutical company agreed to buy eye drug company Eyebiotech for up to $3 billion as it moves to diversify its pipeline and intensifies its acquisition efforts.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for prior
Merck to acquire eye drug company EyeBio for up to $3 bln
07:02am, Wednesday, 29'th May 2024
Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, in the latest acquisition by the U.S. drugmaker as it looks to boost growth.
Merck to buy EyeBio in a deal that could valued at up to $3 billion
06:55am, Wednesday, 29'th May 2024
Merck & Co. Inc. MRK, -2.63% announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.
Merck to Acquire EyeBio
06:45am, Wednesday, 29'th May 2024
RAHWAY, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology
